IL133032A0 - Gene delivery vectors provided with a tissue tropism for smooth muscle cells and/or endothelial cells - Google Patents

Gene delivery vectors provided with a tissue tropism for smooth muscle cells and/or endothelial cells

Info

Publication number
IL133032A0
IL133032A0 IL13303299A IL13303299A IL133032A0 IL 133032 A0 IL133032 A0 IL 133032A0 IL 13303299 A IL13303299 A IL 13303299A IL 13303299 A IL13303299 A IL 13303299A IL 133032 A0 IL133032 A0 IL 133032A0
Authority
IL
Israel
Prior art keywords
tissue tropism
smooth muscle
adenovirus
cells
gene delivery
Prior art date
Application number
IL13303299A
Other versions
IL133032A (en
Original Assignee
Introgene Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgene Bv filed Critical Introgene Bv
Publication of IL133032A0 publication Critical patent/IL133032A0/en
Publication of IL133032A publication Critical patent/IL133032A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for smooth muscle cells and/or endothelial cells. In one aspect said nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably said virus capsid is an adnovirus capsid. Preferably said adenovirus is a subgroup B adenovirus, preferably adenovirus 16. Preferably said tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, preferably cardiovascular diseases.
IL133032A 1998-11-20 1999-11-18 Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells IL133032A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98203921 1998-11-20

Publications (2)

Publication Number Publication Date
IL133032A0 true IL133032A0 (en) 2001-03-19
IL133032A IL133032A (en) 2007-06-03

Family

ID=8234363

Family Applications (1)

Application Number Title Priority Date Filing Date
IL133032A IL133032A (en) 1998-11-20 1999-11-18 Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells

Country Status (12)

Country Link
JP (1) JP4683682B2 (en)
AT (1) ATE296894T1 (en)
AU (1) AU770780B2 (en)
CA (1) CA2318492C (en)
DE (1) DE69925567T2 (en)
ES (1) ES2244145T3 (en)
IL (1) IL133032A (en)
MX (1) MXPA99010682A (en)
NO (1) NO995697L (en)
NZ (1) NZ501214A (en)
WO (1) WO2000031285A1 (en)
ZA (1) ZA997213B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1159438B1 (en) * 1999-03-04 2008-07-30 Crucell Holland B.V. Use of adenoviral vector for synovial cell transduction
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6849446B2 (en) 2000-05-31 2005-02-01 University Of Saskatchewan Modified bovine adenovirus having altered tropism
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP1482052A1 (en) * 2003-05-27 2004-12-01 Cytos Biotechnology AG Modified polypeptides for targeting cell-entry of the adenoviruses of subtype B
BR112019024813A2 (en) 2017-05-26 2020-06-09 Epicentrx Inc recombinant adenoviruses carrying transgenes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
AU731767B2 (en) * 1995-06-15 2001-04-05 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL124654A0 (en) * 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
FR2758822B1 (en) * 1997-01-30 1999-07-02 Centre Nat Rech Scient USE OF A POLYPEPTIDE AS A CELLULAR RECEPTOR OF ADENOVIRUS
FR2761689B1 (en) * 1997-04-02 1999-06-25 Transgene Sa MODIFIED ADENOVIRAL FIBER AND TARGET ADENOVIRUS

Also Published As

Publication number Publication date
AU5960099A (en) 2000-05-25
NO995697L (en) 2000-05-22
ZA997213B (en) 2000-05-22
DE69925567T2 (en) 2006-05-04
NO995697D0 (en) 1999-11-19
CA2318492C (en) 2010-05-11
ES2244145T3 (en) 2005-12-01
NZ501214A (en) 2002-02-01
MXPA99010682A (en) 2002-03-08
ATE296894T1 (en) 2005-06-15
CA2318492A1 (en) 2000-06-02
WO2000031285A1 (en) 2000-06-02
JP4683682B2 (en) 2011-05-18
IL133032A (en) 2007-06-03
AU770780B2 (en) 2004-03-04
JP2000157289A (en) 2000-06-13
DE69925567D1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
ATE403006T1 (en) USE OF AN ADENOVIRUS VECTOR FOR TRANSDUCING SYNOVIAL CELLS
ES2156958T3 (en) ADENOVIRUS-AAV HYBRID VIRUS AND SAME USE METHOD.
EP2292771A3 (en) Sense mRNA therapy
EP1005376A4 (en) Methods and compositions for use in gene therapy for treatment of hemophilia
GR3020557T3 (en) Oligonucleotide alkylphosphonates and alkylphosphonothioates.
WO1999061066A3 (en) Convection-enhanced delivery of aav vectors
ATE231549T1 (en) METHOD FOR PRESERVING INFECTIOUS RECOMBINING VIRUSES, VIRAL AQUEOUS SUSPENSION AND MEDICAL USE THEREOF
HK1071518A1 (en) Improved raav expression systems for genetic modification of specific capsid proteins
EP1927660A3 (en) Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions
DE69906977D1 (en) NUCLEIC ACID COMPLEXES ENCLOSED IN LIPOSOMES
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
DK1783225T3 (en) Structural protein from AAV, its preparation and use
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
IL133032A0 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells and/or endothelial cells
EP0744408A3 (en) Rhesus ob protein and DNA
FR2730411B1 (en) DRUG ASSOCIATION USEFUL FOR IN VIVO TRANSFECTION AND EXPRESSION OF EXOGENES
EP1020529A3 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU1281902A (en) Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
FR2756491B1 (en) TRANSFECTING COMPOSITION USEFUL IN GENE THERAPY ASSOCIATED WITH A RECOMBINANT VIRUS INCORPORATING EXOG ENE NUCLEIC ACID, A NON-VIRAL AND NON-PLASMIDIC TRANSFECTING AGENT
EP1593742A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
WO2000017375A3 (en) Method to treat haemophilia by in vivo gene therapy with retroviral vectors
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
FI964784A0 (en) Virus recombinants, preparation and use in gene therapy
DE69829174D1 (en) EXPRESSION OF A MODIFIED "FOAMY VIRUS ENVELOPE PROTEIN" (SLEEP PROTEIN)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees